tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Taysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating
PremiumRatingsTaysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating
15d ago
Taysha Gene Therapies files automatic mixed securities shelf
Premium
The Fly
Taysha Gene Therapies files automatic mixed securities shelf
15d ago
Taysha Gene Therapies Amends Sales Agreement, Expands Offering
Premium
Company Announcements
Taysha Gene Therapies Amends Sales Agreement, Expands Offering
15d ago
Taysha Gene Therapies initiated with a Strong Buy at Raymond James
PremiumThe FlyTaysha Gene Therapies initiated with a Strong Buy at Raymond James
1M ago
Strategic Advantage and Positive Outlook: Taysha Gene Therapies Maintains Buy Rating
Premium
Ratings
Strategic Advantage and Positive Outlook: Taysha Gene Therapies Maintains Buy Rating
1M ago
Taysha Regains Full Rights to TSHA-102 Program
Premium
Company Announcements
Taysha Regains Full Rights to TSHA-102 Program
1M ago
Taysha Gene Therapies price target raised to $12 from $7 at Baird
PremiumThe FlyTaysha Gene Therapies price target raised to $12 from $7 at Baird
2M ago
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
Premium
The Fly
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
2M ago
Taysha Gene Therapies price target raised to $12 from $7 at Baird
Premium
The Fly
Taysha Gene Therapies price target raised to $12 from $7 at Baird
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100